WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
NASA is looking for new astronautsTale of the state pension underpaid for 20 YEARS: This is Money podcastShed of the Year 2024: We speak to one entrant who created his dream British boozer 'The Dirty Dog'Revealed: The 20 best walks in Britain (and the maps that show you the perfect route)As the Glastonbury 2024 lineup is announced, AI reveals the ultimate headlinersGo on holiday for just £6.40 with the Mail experts' guide to the best bargain tripsTravel fanatic who has used TSA PreCheck for 'her whole life' SLAMS popular serviceGreece gives away 25,000 free holidaysWas the Budget too little, too lateAstronaut Thomas Stafford, commander of Apollo 10, dies aged 93: Air Force three